Foresite Capital Management IV, LLC Diversified Active

CIK: 0001704132 · Show all filings

Period: Q3 2022 (← Previous) (Next →)

Filing Date: Nov 14, 2022

Total Value ($000): $310,955 (100.0% shares, 0.0% debt)

Holdings (8)

— Kinnate Biopharma Inc. 37.2%

Value ($000) $115,576 Shares 9,671,643 Est. Cost $39.78 Unrealized —

— Lyell Immunopharma, Inc. 23.6%

Value ($000) $73,300 Shares 10,000,000 Est. Cost $16.24 Unrealized —

ACRS Aclaris Therapeutics, Inc. 14.2%

Value ($000) $44,198 Shares 2,808,034 Est. Cost $15.18 Unrealized +3.8%

KURA Kura Oncology, Inc. 8.1%

Value ($000) $25,270 Shares 1,849,947 Est. Cost $20.39 Unrealized -24.3%

PHVS Pharvaris N.V. 8.0%

Value ($000) $24,904 Shares 3,246,926 Est. Cost $31.46 Unrealized -50.4%

SNDX Syndax Pharmaceuticals, Inc. 5.3%

Value ($000) $16,581 Shares 690,000 Est. Cost $22.44 Unrealized 0.0%

— Cymabay Therapeutics, Inc. 2.0%

Value ($000) $6,255 Shares 1,787,094 Est. Cost $3.49 Unrealized —

QSI Quantum-Si Incorporated 1.6%

Value ($000) $4,871 Shares 1,771,249 Est. Cost $10.48 Unrealized -69.5%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Kinnate Biopharma Inc.	9,671,643	$115,576	37.2%	$39.78	—	COM	49705R105
—	Lyell Immunopharma, Inc.	10,000,000	$73,300	23.6%	$16.24	—	COM	55083R104
ACRS	Aclaris Therapeutics, Inc.	2,808,034	$44,198	14.2%	$15.18	+3.8%	COM	00461U105
KURA	Kura Oncology, Inc.	1,849,947	$25,270	8.1%	$20.39	-24.3%	COM	50127T109
PHVS	Pharvaris N.V.	3,246,926	$24,904	8.0%	$31.46	-50.4%	COM	N69605108
SNDX	Syndax Pharmaceuticals, Inc.	690,000	$16,581	5.3%	$22.44	0.0%	COM	87164F105
—	Cymabay Therapeutics, Inc.	1,787,094	$6,255	2.0%	$3.49	—	COM	23257D103
QSI	Quantum-Si Incorporated	1,771,249	$4,871	1.6%	$10.48	-69.5%	COM CL A	74765K105